ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells

Table 1 Overview of GSC panel drug screening results

GS ID	Histology	Age	OS	MGMT Blot/Methyl	PARPi	TMZ	Enhancement factor TMZ 50	p-value	Enhancement factor TMZ 100	p-value
GS249	GBM	53	215	- / ND	0.30	0.66	3.06	0.01	2.92	0.03
GS187	GBM	73	394	- / UM	0.12	0.55	2.22	0.00	2.31	0
GS41	AOD	64	1316	ND	0.11	0.61	1.74	0.08	0.92	0.19
GS125	GBM	75	234	+ / UM	0.21	0.71	1.59	0.17	1.78	0.06
GS203	GBM	64	554	- / M	0.39	0.61	1.68	0.01	1.71	0.01
GS184	GBM	50	833	- / M	0.16	0.74	1.40	0.10	1.66	0.01
GS186	GBM	49	792	- / M	0.21	0.74	1.30	0.03	1.49	0
GS224	GBM	58	101	- / M	0.17	0.73	1.15	0.20	1.20	0.03
GS177	GBM	63	843	- / M	0.20	0.76	1.14	0.01	1.15	0.2
GS182	GBM	70	835	- / M	0.38	0.51	1.14	0.02	1.31	0.05
GS200	GBM	57	321	- / ND	0.48	0.35	1.16	0.02	1.18	0.08
GS143	GBM	54	395	- / ND	0.60	0.32	1.17	0.40	1.32	0.09
GS126	GBM	41	962	+ / M	0.27	0.06	1.68	0.02	1.69	0.01
GS79	GBM	71	384	+ / UM	0.11	0.23	2.11	0.00	2.48	0
GS124	GBM	71	1033	+ / ND	0.22	−0.11	1.19	0.40	1.19	0.06
GS148	AOD	82	97	+ / UM	0.20	−0.07	1.15	0.80	1.15	0.06
GS173	GBM	68	138	+ / ND	−0.05	0.14	1.24	0.07	1.73	0.01
GS204	GBM	50	18	+ / UM	0.07	0.02	1.17	0.03	1.17	0.04
GS161	GBM	62	264	+ / M	0.17	−0.02	0.80	0.04	0.80	0.2
GS160	GBM	46	46	+ / UM	0.07	0.16	0.83	0.03	0.75	0

The separation between TMZ sensitive and resistant groups is based on monotherapy results for TMZ 100 μM results. Significance is depicted as a p-value derived Student’s T-test of the most effective single agent compared to combination therapy. For OS, boxes without shading depict patients that were alive at the moment of composing this article. Abbreviations as followed; AOD = Anaplastic Oligodendroglioma, GBM = Glioblastoma Multiforme, OS = Overall Survival in days, MGMT = O6-methylguanine-DNA methyltransferase, Blot = Western blotting results which can be positive (+) or negatieve (−), Methyl = Methylation assay which can be Methylated or UnMethylated). ND = Not determined.

ISSN: 1479-5876